Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

The role of complement in antibody mediated transplant rejection.

Thurman JM, Panzer SE, Le Quintrec M.

Mol Immunol. 2019 Jun 10;112:240-246. doi: 10.1016/j.molimm.2019.06.002. [Epub ahead of print] Review.

PMID:
31195225
2.

CYCLOPHILIN D KNOCKOUT PROTECTS THE MOUSE KIDNEY AGAINST CYCLOSPORIN A-INDUCED OXIDATIVE STRESS.

Klawitter J, Klawitter J, Pennington AT, Kirkpatrick B, Roda G, Kotecha NC, Thurman JM, Christians U.

Am J Physiol Renal Physiol. 2019 Jun 12. doi: 10.1152/ajprenal.00417.2018. [Epub ahead of print]

PMID:
31188033
3.

Complement Therapeutics in Autoimmune Disease.

Thurman JM, Yapa R.

Front Immunol. 2019 Apr 3;10:672. doi: 10.3389/fimmu.2019.00672. eCollection 2019. Review.

4.

Complement Biomarkers of Hemolytic Uremic Syndrome-If Not One Thing, Maybe Another.

Thurman JM.

Mayo Clin Proc. 2018 Oct;93(10):1337-1339. doi: 10.1016/j.mayocp.2018.08.024. No abstract available.

PMID:
30286826
5.

Tissue-targeted complement therapeutics.

Tomlinson S, Thurman JM.

Mol Immunol. 2018 Oct;102:120-128. doi: 10.1016/j.molimm.2018.06.005. Epub 2018 Jul 7. Review.

PMID:
30220307
6.

Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease.

Jalal D, Renner B, Laskowski J, Stites E, Cooper J, Valente K, You Z, Perrenoud L, Le Quintrec M, Muhamed I, Christians U, Klawitter J, Lindorfer MA, Taylor RP, Holers VM, Thurman JM.

J Am Heart Assoc. 2018 Jul 13;7(14). pii: e007818. doi: 10.1161/JAHA.117.007818.

7.

SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [125I]anti-C3d mAb.

Foss CA, Kulik L, Ordonez AA, Jain SK, Michael Holers V, Thurman JM, Pomper MG.

Mol Imaging Biol. 2019 Jun;21(3):473-481. doi: 10.1007/s11307-018-1228-5.

PMID:
29998399
8.

Alternative Pathway Is Essential for Glomerular Complement Activation and Proteinuria in a Mouse Model of Membranous Nephropathy.

Luo W, Olaru F, Miner JH, Beck LH Jr, van der Vlag J, Thurman JM, Borza DB.

Front Immunol. 2018 Jun 22;9:1433. doi: 10.3389/fimmu.2018.01433. eCollection 2018.

9.

Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice.

Mihai S, Hirose M, Wang Y, Thurman JM, Holers VM, Morgan BP, Köhl J, Zillikens D, Ludwig RJ, Nimmerjahn F.

Front Immunol. 2018 Mar 16;9:535. doi: 10.3389/fimmu.2018.00535. eCollection 2018.

10.

The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis.

Okamoto T, Mathai SK, Hennessy CE, Hancock LA, Walts AD, Stefanski AL, Brown KK, Lynch DA, Cosgrove GP, Groshong SD, Cool CD, Schwarz MI, Banda NK, Thurman JM, Yang IV, Holers VM, Schwartz DA.

Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L1-L10. doi: 10.1152/ajplung.00395.2017. Epub 2018 Mar 22.

11.

A Patient with Hemolytic Uremic Syndrome and Kidney Failure.

Thurman JM.

Clin J Am Soc Nephrol. 2018 Jun 7;13(6):933-936. doi: 10.2215/CJN.13191117. Epub 2018 Feb 19. No abstract available.

12.

Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM.

Goetz L, Laskowski J, Renner B, Pickering MC, Kulik L, Klawitter J, Stites E, Christians U, van der Vlag J, Ravichandran K, Holers VM, Thurman JM.

Eur J Immunol. 2018 May;48(5):791-802. doi: 10.1002/eji.201747240. Epub 2018 Feb 22.

13.

Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins.

Antonioli AH, White J, Crawford F, Renner B, Marchbank KJ, Hannan JP, Thurman JM, Marrack P, Holers VM.

J Immunol. 2018 Jan 1;200(1):316-326. doi: 10.4049/jimmunol.1602017. Epub 2017 Nov 29.

14.

Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.

Kwak JW, Laskowski J, Li HY, McSharry MV, Sippel TR, Bullock BL, Johnson AM, Poczobutt JM, Neuwelt AJ, Malkoski SP, Weiser-Evans MC, Lambris JD, Clambey ET, Thurman JM, Nemenoff RA.

Cancer Res. 2018 Jan 1;78(1):143-156. doi: 10.1158/0008-5472.CAN-17-0240. Epub 2017 Nov 8.

15.

Complement factor H-related proteins in IgA nephropathy-sometimes a gentle nudge does the trick.

Thurman JM, Laskowski J.

Kidney Int. 2017 Oct;92(4):790-793. doi: 10.1016/j.kint.2017.05.025.

PMID:
28938951
16.

Mitochondrial cyclophilin D ablation is associated with the activation of Akt/p70S6K pathway in the mouse kidney.

Klawitter J, Pennington A, Klawitter J, Thurman JM, Christians U.

Sci Rep. 2017 Sep 5;7(1):10540. doi: 10.1038/s41598-017-10076-9.

17.

The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases.

Thurman JM, Frazer-Abel A, Holers VM.

Arthritis Rheumatol. 2017 Nov;69(11):2102-2113. doi: 10.1002/art.40219. Epub 2017 Oct 17. Review.

18.

Many drugs for many targets: novel treatments for complement-mediated glomerular disease.

Thurman JM.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i57-i64. doi: 10.1093/ndt/gfw228. Review.

PMID:
28391332
19.

Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response.

Casiraghi F, Azzollini N, Todeschini M, Fiori S, Cavinato RA, Cassis P, Solini S, Pezzuto F, Mister M, Thurman JM, Benigni A, Remuzzi G, Noris M.

Am J Transplant. 2017 Sep;17(9):2312-2325. doi: 10.1111/ajt.14262. Epub 2017 Apr 10.

20.

B cells expressing the transcription factor T-bet drive lupus-like autoimmunity.

Rubtsova K, Rubtsov AV, Thurman JM, Mennona JM, Kappler JW, Marrack P.

J Clin Invest. 2017 Apr 3;127(4):1392-1404. doi: 10.1172/JCI91250. Epub 2017 Feb 27.

21.

Exposure to bisphenols and phthalates and association with oxidant stress, insulin resistance, and endothelial dysfunction in children.

Kataria A, Levine D, Wertenteil S, Vento S, Xue J, Rajendiran K, Kannan K, Thurman JM, Morrison D, Brody R, Urbina E, Attina T, Trasande L, Trachtman H.

Pediatr Res. 2017 Jun;81(6):857-864. doi: 10.1038/pr.2017.16. Epub 2017 Jan 18.

22.

Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b/C3d Interactions.

Hannan JP, Laskowski J, Thurman JM, Hageman GS, Holers VM.

PLoS One. 2016 Nov 4;11(11):e0166200. doi: 10.1371/journal.pone.0166200. eCollection 2016.

23.

Never make assumptions: the complicated role of complement in urinary tract infections.

Thurman JM, Nemenoff RA.

Kidney Int. 2016 Sep;90(3):469-71. doi: 10.1016/j.kint.2016.05.023.

PMID:
27521106
24.

All Things Complement.

Thurman JM, Nester CM.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1856-1866. doi: 10.2215/CJN.01710216. Epub 2016 Jun 23. Review.

25.

Targeting the complement cascade: novel treatments coming down the pike.

Thurman JM, Le Quintrec M.

Kidney Int. 2016 Oct;90(4):746-52. doi: 10.1016/j.kint.2016.04.018. Epub 2016 Jun 18. Review.

26.

New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities.

Holers VM, Tomlinson S, Kulik L, Atkinson C, Rohrer B, Banda N, Thurman JM.

Semin Immunol. 2016 Jun;28(3):260-7. doi: 10.1016/j.smim.2016.05.007. Epub 2016 Jun 6. Review.

27.

Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood.

Blatt AZ, Saggu G, Kulkarni KV, Cortes C, Thurman JM, Ricklin D, Lambris JD, Valenzuela JG, Ferreira VP.

J Immunol. 2016 Jun 1;196(11):4671-4680. doi: 10.4049/jimmunol.1600040. Epub 2016 Apr 25.

28.

Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury.

Laskowski J, Renner B, Le Quintrec M, Panzer S, Hannan JP, Ljubanovic D, Ruseva MM, Borza DB, Antonioli AH, Pickering MC, Holers VM, Thurman JM.

Kidney Int. 2016 Jul;90(1):109-22. doi: 10.1016/j.kint.2016.02.036. Epub 2016 May 7.

29.

Complement Factor B Production in Renal Tubular Cells and Its Role in Sodium Transporter Expression During Polymicrobial Sepsis.

Li D, Zou L, Feng Y, Xu G, Gong Y, Zhao G, Ouyang W, Thurman JM, Chao W.

Crit Care Med. 2016 May;44(5):e289-99. doi: 10.1097/CCM.0000000000001566.

30.

Annexin A2 Enhances Complement Activation by Inhibiting Factor H.

Renner B, Tong HH, Laskowski J, Jonscher K, Goetz L, Woolaver R, Hannan J, Li YX, Hourcade D, Pickering MC, Holers VM, Thurman JM.

J Immunol. 2016 Feb 1;196(3):1355-65. doi: 10.4049/jimmunol.1500793. Epub 2016 Jan 4.

31.

The Complement System and Antibody-Mediated Transplant Rejection.

Stites E, Le Quintrec M, Thurman JM.

J Immunol. 2015 Dec 15;195(12):5525-31. doi: 10.4049/jimmunol.1501686. Review.

32.

γδ T cells protect against LPS-induced lung injury.

Wehrmann F, Lavelle JC, Collins CB, Tinega AN, Thurman JM, Burnham EL, Simonian PL.

J Leukoc Biol. 2016 Feb;99(2):373-86. doi: 10.1189/jlb.4A0115-017RR. Epub 2015 Oct 1.

33.

Complement Activation in Patients with Focal Segmental Glomerulosclerosis.

Thurman JM, Wong M, Renner B, Frazer-Abel A, Giclas PC, Joy MS, Jalal D, Radeva MK, Gassman J, Gipson DS, Kaskel F, Friedman A, Trachtman H.

PLoS One. 2015 Sep 3;10(9):e0136558. doi: 10.1371/journal.pone.0136558. eCollection 2015.

34.

Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus.

Thurman JM, Serkova NJ.

Version 2. F1000Res. 2015 Jun 16 [revised 2015 Jan 1];4:153. doi: 10.12688/f1000research.6587.2. eCollection 2015. Review.

35.

Getting over our Immune-Complex - C5a receptor blockade is the answer.

Thurman JM.

Cell Mol Immunol. 2017 Mar;14(3):319-320. doi: 10.1038/cmi.2015.54. Epub 2015 Jul 6. No abstract available.

36.

IgM exacerbates glomerular disease progression in complement-induced glomerulopathy.

Panzer SE, Laskowski J, Renner B, Kulik L, Ljubanovic D, Huber KM, Zhong W, Pickering MC, Holers VM, Thurman JM.

Kidney Int. 2015 Sep;88(3):528-37. doi: 10.1038/ki.2015.120. Epub 2015 May 6.

37.

A high-performance liquid chromatography-tandem mass spectrometry-based targeted metabolomics kidney dysfunction marker panel in human urine.

Klepacki J, Klawitter J, Klawitter J, Thurman JM, Christians U.

Clin Chim Acta. 2015 Jun 15;446:43-53. doi: 10.1016/j.cca.2015.04.005. Epub 2015 Apr 11.

38.

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

Evgin L, Acuna SA, Tanese de Souza C, Marguerie M, Lemay CG, Ilkow CS, Findlay CS, Falls T, Parato KA, Hanwell D, Goldstein A, Lopez R, Lafrance S, Breitbach CJ, Kirn D, Atkins H, Auer RC, Thurman JM, Stahl GL, Lambris JD, Bell JC, McCart JA.

Mol Ther. 2015 Jun;23(6):1066-1076. doi: 10.1038/mt.2015.49. Epub 2015 Mar 25.

39.

The alternative complement component factor B regulates UV-induced oedema, systemic suppression of contact and delayed hypersensitivity, and mast cell infiltration into the skin.

Byrne SN, Hammond KJ, Chan CY, Rogers LJ, Beaugie C, Rana S, Marsh-Wakefield F, Thurman JM, Halliday GM.

Photochem Photobiol Sci. 2015 Apr;14(4):801-6. doi: 10.1039/c4pp00399c.

PMID:
25645888
40.

Complement in kidney disease: core curriculum 2015.

Thurman JM.

Am J Kidney Dis. 2015 Jan;65(1):156-68. doi: 10.1053/j.ajkd.2014.06.035. Epub 2014 Oct 18. Review. No abstract available.

41.

Deletion of the complement C5a receptor alleviates the severity of acute pneumococcal otitis media following influenza A virus infection in mice.

Tong HH, Lambert G, Li YX, Thurman JM, Stahl GL, Douthitt K, Clancy C, He Y, Bowman AS.

PLoS One. 2014 Apr 16;9(4):e95160. doi: 10.1371/journal.pone.0095160. eCollection 2014.

42.

New anti-complement drugs: not so far away.

Thurman JM.

Blood. 2014 Mar 27;123(13):1975-6. doi: 10.1182/blood-2014-02-555805.

43.

Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.

Locatelli M, Buelli S, Pezzotta A, Corna D, Perico L, Tomasoni S, Rottoli D, Rizzo P, Conti D, Thurman JM, Remuzzi G, Zoja C, Morigi M.

J Am Soc Nephrol. 2014 Aug;25(8):1786-98. doi: 10.1681/ASN.2013050450. Epub 2014 Feb 27.

44.

Mycophenolate mofetil enhances the negative effects of sirolimus and tacrolimus on rat kidney cell metabolism.

Klawitter J, Klawitter J, Schmitz V, Shokati T, Epshtein E, Thurman JM, Christians U.

PLoS One. 2014 Jan 30;9(1):e86202. doi: 10.1371/journal.pone.0086202. eCollection 2014.

45.

Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imaging.

Thurman JM, Serkova NJ.

Adv Chronic Kidney Dis. 2013 Nov;20(6):488-99. doi: 10.1053/j.ackd.2013.06.001. Review.

46.

C3 glomerulopathy: consensus report.

Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT.

Kidney Int. 2013 Dec;84(6):1079-89. doi: 10.1038/ki.2013.377. Epub 2013 Oct 30.

47.

The role of the complement system in acute kidney injury.

McCullough JW, Renner B, Thurman JM.

Semin Nephrol. 2013 Nov;33(6):543-56. doi: 10.1016/j.semnephrol.2013.08.005. Review.

48.

Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis.

Zou L, Feng Y, Li Y, Zhang M, Chen C, Cai J, Gong Y, Wang L, Thurman JM, Wu X, Atkinson JP, Chao W.

J Immunol. 2013 Dec 1;191(11):5625-35. doi: 10.4049/jimmunol.1301903. Epub 2013 Oct 23.

49.

Cyclosporine induces endothelial cell release of complement-activating microparticles.

Renner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE, Christians U, Thurman JM.

J Am Soc Nephrol. 2013 Nov;24(11):1849-62. doi: 10.1681/ASN.2012111064. Epub 2013 Oct 3.

50.

Renal ischemia-reperfusion injury amplifies the humoral immune response.

Fuquay R, Renner B, Kulik L, McCullough JW, Amura C, Strassheim D, Pelanda R, Torres R, Thurman JM.

J Am Soc Nephrol. 2013 Jun;24(7):1063-72. doi: 10.1681/ASN.2012060560. Epub 2013 May 2.

Supplemental Content

Loading ...
Support Center